<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gwon, Hyeon-Cheol</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of 6 and 12 Months of DAT after Implantation of a DES</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">Six months of dual antiplatelet therapy (DAT; aspirin and clopidogrel) was noninferior to 12 months of DAT after percutaneous coronary intervention with implantation of a drug-eluting stent, according to findings of the EXCELLENT trial.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>